Tags

Type your tag names separated by a space and hit enter

Cardiac and systemic haemodynamic complications of liver cirrhosis.
Scand Cardiovasc J. 2009 Aug; 43(4):218-25.SC

Abstract

Cardiovascular complications of liver cirrhosis include cardiac dysfunction and abnormalities in the central-, splanchnic,- and peripheral circulation. Vasodilatation prevails, but vascular beds with various degrees of reduced and increased haemodynamic resistance are the results of massive activation of powerful homeostatic, regulatory systems. Cirrhotic cardiomyopathy implies systolic and diastolic dysfunction and electrophysiological abnormalities, an entity that is different from alcoholic heart muscle disease. Being often clinical latent, cirrhotic cardiomyopathy can be unmasked by physical and pharmacological strain. Cardiac failure is an important cause of mortality after liver transplantation and stressful procedures as insertions of transjugular intrahepatic portal systemic shunt (TIPS), peritoneal venous shunting, and other types of surgery. Improvement of liver function has been shown to reverse the cardiovascular complications. The clinical significance is an important topic for future research. At present, no specific treatment can be recommended, and the cardiac failure in cirrhosis should be treated as in non-cirrhotic patients with sodium restriction, diuretics, and beta-adrenergic blocking agents. Special care should be taken with the use of ACE-inhibitors and angiotensin antagonist in these patients.

Authors+Show Affiliations

Department of Clinical Physiology 239, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Hvidovre, Denmark. jens.h.henriksen@hvh.regionh.dkNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19145534

Citation

Henriksen, Jens H., and Søren Møller. "Cardiac and Systemic Haemodynamic Complications of Liver Cirrhosis." Scandinavian Cardiovascular Journal : SCJ, vol. 43, no. 4, 2009, pp. 218-25.
Henriksen JH, Møller S. Cardiac and systemic haemodynamic complications of liver cirrhosis. Scand Cardiovasc J. 2009;43(4):218-25.
Henriksen, J. H., & Møller, S. (2009). Cardiac and systemic haemodynamic complications of liver cirrhosis. Scandinavian Cardiovascular Journal : SCJ, 43(4), 218-25. https://doi.org/10.1080/14017430802691528
Henriksen JH, Møller S. Cardiac and Systemic Haemodynamic Complications of Liver Cirrhosis. Scand Cardiovasc J. 2009;43(4):218-25. PubMed PMID: 19145534.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cardiac and systemic haemodynamic complications of liver cirrhosis. AU - Henriksen,Jens H, AU - Møller,Søren, PY - 2009/1/16/entrez PY - 2009/1/16/pubmed PY - 2009/10/3/medline SP - 218 EP - 25 JF - Scandinavian cardiovascular journal : SCJ JO - Scand Cardiovasc J VL - 43 IS - 4 N2 - Cardiovascular complications of liver cirrhosis include cardiac dysfunction and abnormalities in the central-, splanchnic,- and peripheral circulation. Vasodilatation prevails, but vascular beds with various degrees of reduced and increased haemodynamic resistance are the results of massive activation of powerful homeostatic, regulatory systems. Cirrhotic cardiomyopathy implies systolic and diastolic dysfunction and electrophysiological abnormalities, an entity that is different from alcoholic heart muscle disease. Being often clinical latent, cirrhotic cardiomyopathy can be unmasked by physical and pharmacological strain. Cardiac failure is an important cause of mortality after liver transplantation and stressful procedures as insertions of transjugular intrahepatic portal systemic shunt (TIPS), peritoneal venous shunting, and other types of surgery. Improvement of liver function has been shown to reverse the cardiovascular complications. The clinical significance is an important topic for future research. At present, no specific treatment can be recommended, and the cardiac failure in cirrhosis should be treated as in non-cirrhotic patients with sodium restriction, diuretics, and beta-adrenergic blocking agents. Special care should be taken with the use of ACE-inhibitors and angiotensin antagonist in these patients. SN - 1651-2006 UR - https://www.unboundmedicine.com/medline/citation/19145534/Cardiac_and_systemic_haemodynamic_complications_of_liver_cirrhosis_ L2 - https://www.tandfonline.com/doi/full/10.1080/14017430802691528 DB - PRIME DP - Unbound Medicine ER -